FRANKLIN, Mass., March 22, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that John Garibotto and Kenneth Gary, who collectively have nearly fifty years of medical device and diagnostics experience, have joined Echo Therapeutics' senior management team as part of the company's plan to accelerate the development of the Symphony System and other new products contemplated in the Company's growth strategy.
John Garibotto joins as Vice President of Operations. In this newly created position, he will oversee Echo's product development, engineering, manufacturing, regulatory and quality functions.
Kenneth Gary joins as Vice President of Research, clinical and new products. He will oversee new product research activities and the design and execution of supporting clinical trials.
"John's and Ken's significant experience in complete product development from ideation to final FDA approval of medical devices and diagnostics will ensure the aggressive product development and successful clinical validation of our Symphony tCGM System," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We are extremely pleased to have such highly valuable, successful and seasoned industry veterans join the Company as we move toward our final goal of FDA marketing clearance of Symphony. We plan to leverage their deep domain expertise as Echo looks to broaden its product pipeline over the coming year."
Mr. Garibotto has 23 years of medical device experience with a proven track record of building and leading large multi-disciplinary teams through ideation, regulatory approval, commercialization and mass m